Post-triptan era for the treatment of acute migraine

Current Pain and Headache Reports

Volumn 8, Issue 5, 2004, Pages 393-398

  Goadsby, Peter J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ANANDAMIDE; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CANNABINOID 1 RECEPTOR; CAPSAICIN; DRONABINOL; GR 190178; NEUROKININ A; NOCICEPTIN RECEPTOR; OLVANIL; PLACEBO; PNU 142633; SEROTONIN 1 AGONIST; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN RECEPTOR; SUBSTANCE P; SUMATRIPTAN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VASOCONSTRICTOR AGENT;

ACUTE DISEASE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CLUSTER HEADACHE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; MIGRAINE; NOCICEPTION; NONHUMAN; PROTEIN SECRETION; RECEPTOR BLOCKING; REVIEW; THORAX PAIN; TREATMENT PLANNING; TRIGEMINAL NERVE;

EID: 5144222469     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-996-0013-3     Document Type: Review

References (102)

1. Goadsby PJ: The pharmacology of headache. Prog Neurobiol 2000, 62:509-525.
2. Doenicke A, Siegel E, Hadoke M, Perrin VL: Initial clinical study of AH25086B (5-HT1-like agonist) in the acute treatment of migraine. Cephalalgia 1987, 7:437-438.
3. Doenicke A, Brand J, Perrin VL: Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1988, I:1309-1311.
4. Dodick D, Lipton RB, Martin V, et al.: Consensus Statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004, 44: 414-425.
5. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ: Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675.
6. Kimball RW, Friedman AP, Vallejo E: Effect of serotonin in migraine patients. Neurology 1960, 10:107-111.
7. Lance JW, Anthony M, Hinterberger H: The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 1967, 7:93-102.
8. Humphrey PP, Feniuk W, Perren MJ, et al.: Serotonin and migraine. Ann N Y Acad Sci 1990, 600:587-598.
9. Lance JW, Fine RD, Curran DA: An evaluation of methysergide in the prevention of migraine and other vascular headaches. Med J Aust 1963, 1:814-818.
10. Johnston BM, Saxena PR: The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 1978, 63:541-549.
11. Goadsby PJ, Lipton RB, Ferrari MD: Migraine: current understanding and treatment. N Engl J Med 2002, 346: 257-270.
12. Goadsby PJ, Edvinsson L: Neurovascular control of the cerebral circulation. In Cerebral Blood Flow and Metabolism, edn 2. Edited by Edvinsson L, Krause DN. Philadelphia: Lippincott Williams & Wilkins; 2002:172-188.
13. De Vries P, Villalon CM, Saxena PR: Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 1999, 375:61-74.
14. Goadsby PJ, Kaube H: Animal models of headache. In The Headaches, edn 2. Edited by Olesen J, Tfelt-Hansen P, Welch KM. Philadelphia: Lippincott Williams & Wilkins; 2000:195-202.
15. Saxena PR, De Boer MO: Pharmacology of antimigraine drugs. J Neurol 1991, 238:S28-S35.
16. Saxena PR, Cairo-Rawlins WI: Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. Eur J Pharmacol 1979, 58:305-312.
17. Markowitz S, Saito K, Moskowitz MA: Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 1987 , 7:4129-4136.
18. Markowitz S, Saito K, Moskowitz MA: Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids: a possible mechanism of action in vascular headache. Cephalalgia 1988, 8:83-91.
19. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL: Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat: intravital microscope studies. Cephalalgia 1997, 17:525-531.
20. Kaube H, Hoskin KL, Goadsby PJ: Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia 1992, 12:133-136.
21. Branchek T, Archa JE: Recent advances in migraine therapy. In Central Nervous System Disease. Edited by Robertson DW. Burlington, MA: Academic Press; 1997:1-10.
22. Phebus LA, Johnson KW, Zgombick JM, et al.: Characterization of LY334370 as a pharmacological tool to study 5HT1F receptor-binding affinities, brain penetration, and activity in the neurogenic dural inflammation model of migraine. Life Sci 1997, 61:2117-2126.
23. Johnson KW, Schaus JM, Durkin MM, et al.: 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997, 8:2237-2240.
24. Cohen ML, Schenck K: 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin (1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 1999, 290:935-939.
25. Razzaque Z, Heald MA, Pickard JD, et al.: Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol 1999, 47:75-82.
26. Goldstein DJ, Roon KI, Offen WW et al.: Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomized, controlled trial. Lancet 2001, 358:1230-1234.
27. Castro ME, Pascual J, Romon T, et al.: Differential distribution of [3H]sumatriptan binding sites (5-HT1B, 5-HT1D and 5-HT1F receptors) in human brain: focus on brain stem and spinal cord. Neuropharmacology 1997, 36:535-542.
28. Pascual J, Arco CD, Romon T, et al.: [3H] Sumatriptan binding sites in human brain: regional-dependent labeling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 1996, 295: 271-274.
29. Waeber C, Moskowitz MA: [3H]sumatriptan labels both 5-HT1D and 5HT1F receptor bindings sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995, 352:263-275.
30. Fugelli A, Moret C, Fillion G: Autoradiographic localization of 5-HT1E and 5-HT1F binding sites in rat brain: effect of serotonergic lesioning. J Recept Signal Transduct Res 1997, 17:631-645.
31. Bouchelet I, Cohen Z, Case B, Hamel E: Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996, 50:219-223.
32. Mitsikostas DD, Sanchez del Rio M, Moskowitz MA, Waeber C: Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur J Pharmacol 1999, 369:271-277.
33. Goadsby PJ, Classey JD: Evidence for 5-HT1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 2003, 122:491-498.
34. Maneesi S, Akerman S, Lasalandra MP, et al.: Electron microscopic demonstration of pre- and postsynaptic 5-HT1D and 5-HT1F receptor immunoreactivity (IR) in the rat trigeminocervical complex (TCC): new therapeutic possibilities for the triptans. Cephalalgia 2004, 24:148.
35. Waeber C, Cutrer FM, Yu XJ, Moskowitz MA: The selective 5-HT1D receptor agonist U-109291 blocks dural plasma extravasation and c-fos expression in the trigeminal nucleus caudalis. Cephalalgia 1997, 17:401.
36. Potrebic S, Ahan AH, Skinner K, et al.: Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 2003, 23:10988-10997.
37. Ahn AH, Fields HL, Basbaum AI: The triptan receptor 5HT1D is dynamically regulated in the central terminal of primary afferents in models of pain. Neurology 2004, 62:A440-A441.
38. Pregenzer JF, Alberts GL, Block JH, et al.: Characterization of ligand-binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla, and rhesus monkey in comparison with those from the human and guinea pig receptors. Neurosci Lett 1997, 235:117-120.
39. Gomez-Mancilla B, Cutler NR, Leibowitz MT, et al.: Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 2001, 21: 727-732.
40. Pregenzer JF, Alberts GL, Im WB, et al.: Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Br J Pharmacol 1999, 127:468-472.
41. McCall RB, Huff R, Chio CL, et al.: Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT 1D receptor agonist PNU-142633. Cephalalgia 2002, 22:799-806.
42. Fleishaker JC, Pearson LK, Knuth DW, et al.: Pharmacokenetics and tolerability of a novel 5-HT1D agonist, PNU-142633F. Int J Clin Pharmacol Ther 1999, 37:487-492.
43. Edvinsson L, Ekman R, Jansen I, et al.: Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab 1987, 7: 720-728.
44. Goadsby PJ, Edvinsson L, Ekman R: Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988, 23:193-196.
45. Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28:183-187.
46. Gallai V, Sarchielli P, Floridi A, et al.: Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995, 15:384-390.
47. Goadsby PJ, Edvinsson L: Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994, 117:427-434.
48. Fanciullacci M, Alessandri M, Figini M, [et al.: Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995, 60:119-123.
49. Goadsby PJ, Edvinsson L: Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994, 34:394-399.
50. Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.
51. Zagami AS, Goadsby PJ, Edvinsson L: Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990, 16:69-75.
52. Knight YE, Edvinsson L, Goadsby PJ: Blockade of CGRP release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. Neuropeptides 1999, 33:41-46.
53. Knight YE, Edvinsson L, Goadsby PJ: 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity. Neuropharmacology 2001, 40:520-525.
54. Doods H, Hallermayer G, Wu D, et al.: Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000, 129:420-423.
55. Moreno MJ, Abounader R, Hebert E, et al.: Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002, 42:568-576.
56. Storer RJ, Akerman S, Goadsby PJ: Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004, 142:1171-1181.
57. Olesen J, Diener HC, Husstedt IW, et al.: Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med 2004, 350:1104-1110.
58. Petersen KA, Birk S, Lassen LH, et al.: The novel CGRP-antagonist, BIBN4096BS, does not affect the cerebral hemodynamics in healthy volunteers. Cephalalgia 2003, 23:729.
59. Petersen KA, Lassen LH, Birk S, Olesen J: The effect of the nonpeptide CGRP-antagonist, BIBN406BS, on human-alpha CGRP-induced headache and hemodynamics in healthy volunteers. Cephalalgia 2003, 23:725.
60. Sawynok J: Adenosine receptor activation and nociception. Eur J Pharmacol 1998, 347:1-11.
61. Sawynok J: Purines in pain management. Curr Opin Central Peripher Nerv Syst Investigation Drugs 1999, 1:27-38.
62. Paalzow G, Paalzow L: The effects of caffeine and theophylline on nociceptive stimulation in the rat. Acta Pharmacol Toxicol 1973, 32:22-32.
63. Sawynok J, Sweeney MI, White TD: Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br J Pharmacol 1986, 88:923-930.
64. Sjolund KF, Sollevi A, Segerdahl M, et al.: Intrathecal and systemic R-phenylisopropyadenosine reduces scratching behavior in a rat mononeuropathy model. Neuroreport 1996, 7:1856-1860.
65. DeLander GE, Hopkins GJ: Spinal adenosine modulates descending antinociceptive pathways stimulated by morphine. J Pharmacol Exp Ther 1986, 239:88-93.
66. DeLander GE, Hopkins CJ: Interdependence of spinal adenosinergic, serotonergic, and noradrenergic systems mediating antinociception. Neuropharmacology 1987, 26:1791-1794.
67. Schindler M, Harris CA, Hayes B, et al.: Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci Lett 2001, 297:211-215.
68. Gurden MF, Coates J, Ellis F, et al.: Functional characterisation of three adenosine receptor types. Br J Pharmacol 1993, 109:693-698.
69. Sheehan MJ, Wilson DJ, Cousins R, Giles H: Relative intrinsic efficacy of adenosine A1 receptor agonists measured using functional and radioligand binding. Br J Pharmacol 2000, 131:34P.
70. Goadsby PJ, Hoskin KL, Storer RJ, et al.: Adenosine (A1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002, 125:1392-1401.
71. Santicioli P, Delbianco E, Maggi CA: Adenosine A1 receptors mediate the presynaptic inhibition of calcitonin gene-related peptide release by adenosine in the rat spinal cord. Eur J Pharmacol 1993, 231:139-142.
72. Honey AC, Bland-Ward PA, Connor HE, et al.: Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat. Cephalalgia 2000, 22:260-264.
73. Kaube H, Katsarava Z, Kaufer T, et al.: A new method to increase the nociception specificity of the human blink reflex. Clin Neurophysiol 2000, 111:413-416.
74. Giffin NJ, Kowacs F, Libri V, et al.: Effect of adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 2003, 23:287-292.
75. Meunier J, Mouledous L, Topham CM: The nociceptin (ORL1) receptor: molecular cloning and functional architecture. Peptides 2000, 21:893-900.
76. Reinscheid RK, Nothacker H, Civelli O: The orphanin FQ/nociceptin gene: structure, tissue distribution of expression, and functional implications obtained from knockout mice. Peptides 2000, 21:901-906.
77. Mogil JS, Pasternak GW: The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Physiol Rev 2001, 53:381-415.
78. Reinscheid RK, Nothacker HP, Bourson A, et al.: Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 1995, 270:792-794.
79. Darland T, Grandy DK: The orphanin FQ system: an emerging target for the management of pain? Br J Anaesth 1998, 81:29-37.
80. Xu X, Grass S, Hao J, et al.: Nociceptin/orphanin FQ in spinal nociceptive mechanisms under normal and pathological conditions. Peptides 2000, 21:1031-1036.
81. Hou M, Tajti J, Uddman R, Edvinsson L: Demonstration of nociception positive cells and opioid-receptor like-1 in human trigeminal ganglion. Cephalalgia 2001, 21:402.
82. Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL: Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia 1997, 17:518-524.
83. Bartsch T, Akerman S, Goadsby PJ: The ORL-1 (NOP1) receptor ligand nociceptin/orphanin FQ (N/OFQ) inhibits neurogenic vasodilatation in the rat. Neuropharmacology 2002, 43: 991-998.
84. Okuda-Ashitaka E, Minami T, Tachibana S, et al.: Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 1998, 392:286-289.
85. Okuda-Ashitaka E, Ito S: Nocistatin: a novel neuropeptide encoded by the gene for the nociceptin/orphanin FQ precursor. Peptides 2000, 21:1101-1109.
86. Caterina MJ, Schumacher MA, Tominaga M, et al.: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
87. Joo F, Szolcsanyi J, Jancso-Gabor A: Mitochondrial alterations in the spinal ganglion cells of the rat accompanying the long-lasting sensory disturbance induced by capsaicin. Life Sci 1969, 8:621-626.
88. Guo A, Vulchanova L, Wang J, et al.: Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor, and 1B4 binding sites. Eur J Neurosci 1999, 11:946-958.
89. Ichikawa H, Sugimoto T: VR1-immunoreactive primary sensory neurons in the rat trigeminal ganglion. Brain Res 2001, 890:184-188.
90. Hou M, Uddman R, Tajti J, et al.: Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci Lett 2002, 330:223-226.
91. Akerman S, Kaube H, Goadsby PJ: Vanilloid type 1 receptor (VR1) evoked CGRP release plays a minor role in causing dural vessel dilation via the trigeminovascular system. Br J Pharmacol 2003, 140:718-724.
92. Matsuda LA, Lolait SJ, Brownstein MJ, et al.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
93. Hoehe MR, Caenazzo L, Martinez MM, et al.: Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. Nat New Biol 1991, 3:880-885.
94. Devane WA, Hanus L, Breuer A, et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science1992, 258:1946-1949.
95. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
96. Dewey WL: Cannabinoid pharmacology. Pharmacol Rev 1986, 38:151-178.
97. Smith PB, Compton DR, Welch SP, et al.: The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994, 270: 219-227.
98. Adams IB, Compton DR, Martin BR: Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 1998, 284:1209-1217.
99. Crawley JN, Corwin RL, Robinson JK, et al.: Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav 1993, 46:967-972.
100. Akerman S, Kaube H, Goadsby PJ: Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 2004, 309:56-63.
101. Zygmunt PM, Petersson J, Andersson DA, et al.: Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.
102. Akerman S, Kaube H, Goadsby PJ: Anandamide shows both cannabinoid and vanilloid properties in an in vivo model of trigeminovascular mediated head pain. Cephalalgia 2003, 23:646.